<DOC>
	<DOCNO>NCT02100046</DOCNO>
	<brief_summary>Currently , establish voltage-gated calcium channel modulate pain perception due influence neuronal transmission excitability . In past , attention focus modulation high voltage activate calcium channel . More recently , scientific interest proven low voltage activate calcium channel , also call T-type channel . The data literature show significant involvement channel physiology nociception pathophysiology acute chronic pain . Moreover , several animal pain model ( acute , neuropathic , inflammatory ) , T-type channel inhibition alleviate painful behaviour . Analgesics treatment available clinic ineffective patient chronic pain ( neuropathic , inflammatory ) often induce deleterious side effect . Thus , clinical use selective inhibitor T-type channel could help development new therapy treatment neuropathic pain ( prevalence = 5-8 % ) , also pharmaco-economic impact due low selling price inhibitor currently available : Zarontin® . The purpose study assess effectiveness ethosuximide ( Zarontin® ) pain symptom quality life patient neuropathic traumatic pain compare control group .</brief_summary>
	<brief_title>Assessment Effectiveness Ethosuximide Treatment Traumatic Neuropathic Pain</brief_title>
	<detailed_description>This multicentre , parallel-group , double-blind , randomised clinical trial compare ethosuximide inactive control treatment neuropathic traumatic pain , assess numerical rating scale quality life questionnaire .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Ethosuximide</mesh_term>
	<criteria>Age ≥ 18 year Traumatic neuropathy postsurgical ( exclude amputation ) Neuropathic Pain Diagnostic DN4 ≥ 4 positive IASP criterion ENS pain ≥ 4 ALT , AST , PAL , normal GGT , creatinine &lt; 133μmol / L , hematocrit &gt; 38 % , βHCG Patients affiliated French Social Security Patients free inform consent obtain Pregnancy breastfeed Diabetic neuropathy , postherpetic neuralgia , cancer chemotherapyinduced , Patients impair glucose tolerance , Medical surgical history incompatible study , History renal disease / liver , Addiction alcohol / drug , Taking antiepileptic family carboxamides ethosuximide Use St. John 's wort , Allergy succinimides ( ethosuximide , methsuximide , phensuximide ) Psychotic disorder , Patients epilepsy , Patient exclusion period , total allowable compensation exceed Patients undergoing measure legal protection ( guardianship , supervision ... )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Ethosuximide</keyword>
	<keyword>Neuropathic pain</keyword>
	<keyword>Pain</keyword>
	<keyword>Quality life</keyword>
	<keyword>Neuropathic Pain diagnostic questionnaire ≥ 4</keyword>
	<keyword>Analgesic treatment failure least 3 month</keyword>
</DOC>